<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02246244</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002159-25</org_study_id>
    <secondary_id>2008/1388</secondary_id>
    <nct_id>NCT02246244</nct_id>
  </id_info>
  <brief_title>Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress</brief_title>
  <acronym>TADDOR</acronym>
  <official_title>Randomized, Double Blind, Efficacy Study of Escitalopram Versus Placebo in ENT Cancer Patients Suffering From Emotional Distress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Escitalopram is an antidepressant inhibitor of the serotonin reuptake. On the market in&#xD;
      France since 2002.&#xD;
&#xD;
      Prevalence of emotional distress in patients with cancer is 30-50%. this prevalence may vary&#xD;
      regarding the tumor localisation, the population, intensity of the symptoms...&#xD;
&#xD;
      Incidence of ENT cancer is highly significant in France, it is one of the most important in&#xD;
      the world 37 out of 100 000. it is in patients with ENT cancer that the prevalence of&#xD;
      depression is the most important (22%-57%).&#xD;
&#xD;
      Researches appears necessary to assessed the efficacy of antidepressant treatments with as&#xD;
      primary objective not only the decrease of depressive symptoms but also an ensemble of physic&#xD;
      and psychological symptoms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of treatment by Escitalopram on depressive symptoms</measure>
    <time_frame>Assessed 3 months after randomization</time_frame>
    <description>Assessed using HADS scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment on emotional distress</measure>
    <time_frame>Assessed 3 months after randomization</time_frame>
    <description>Assessed using HADS scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>ENT Cancer</condition>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ENT cancer of stage I to IVb that have to go under surgery and/or&#xD;
             radiotherapy and/or chemotherapy as first line treatment. It may be a primary cancer&#xD;
             or a new localisation.&#xD;
&#xD;
          -  Total score on HADS scale &gt;11&#xD;
&#xD;
          -  Patients aged from 18 to 75 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  OMS &lt; 2, hospitalized or ambulatory&#xD;
&#xD;
          -  Are authorized to inclusion, psychoactive treatments at stable dosage for two weeks&#xD;
             for benzodiazepins, neuroleptics, antihistaminics or other anxiolytics or hypnotics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in palliative treatments&#xD;
&#xD;
          -  Previous bipolar disorder or schizophrenia&#xD;
&#xD;
          -  Major depressive episode with severity criteria&#xD;
&#xD;
          -  Suicidal patients&#xD;
&#xD;
          -  Acute infection&#xD;
&#xD;
          -  ASAT/ALAT &gt;3N&#xD;
&#xD;
          -  Creatinine clearance &lt;30 ml/mn&#xD;
&#xD;
          -  Natremia inferior to the laboratory standard&#xD;
&#xD;
          -  For alcoholic patients non abstinent at the time of inclusion, previous &quot;delirium&#xD;
             tremens&quot;&#xD;
&#xD;
          -  Previous upper gist bleeding&#xD;
&#xD;
          -  Inefficacy or intolerance of previous treatment by escitalopram&#xD;
&#xD;
          -  Not compatible concomitant treatment:&#xD;
&#xD;
          -  Other antidepressive than escitalopram (except clonazepam)&#xD;
&#xD;
          -  all hypnotics (except zolpidem)&#xD;
&#xD;
          -  all anxiolytics (except clonazepam, clorazepate and diazepam)&#xD;
&#xD;
          -  medical treatment for smoking addiction like bupropion or varenicline&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients under guardianship&#xD;
&#xD;
          -  Patients without insurance&#xD;
&#xD;
          -  Impossibility to follow the protocol for geographical, social or psychic reasons&#xD;
&#xD;
          -  Insufficient knowledge of French&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2014</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

